|
|
|
| HOME | LATEST EPISODE | EPISODE ARCHIVE | SPONSORSHIP | ABOUT US |
 |
|
|
|
|
|
PharmaVentures Business Review - Episode ArchiveGlide Pharma: The transition from drug delivery to specialty pharma (February 2007)Fintan Walton talks to Charles Potter, CEO, Glide Pharma, about inventing the Glide technology and his subsequent setting up of Glide Pharmaceutical Technologies. After covering Charles’ experience at PowderJect Pharmaceuticals, Fintan and Charles discuss how the company, originally set up as the drug delivery firm Caretek Medical, evolved into a specialty pharmaceutical company. Today, Glide Pharma has three generic products in its pipeline, in addition to partnerships that include one with a top five pharmaceutical company. These applications of the Glide technology have been applied only to products already available on the market, but this may change as the company moves forward.
Xanthus: Evolving business strategies (February 2007)Fintan Walton talks to Mike Boss, Chief Business Officer, Xanthus Pharmaceuticals, about his role in the evolution of Xanthus, a biopharmaceutical company founded in 2001. After covering Mike's industry experience, Fintan and Mike discuss how Xanthus morphed from a personalised medicine company into a drug discovery firm, which today has five promising molecules in its product pipeline. All of the company's products are focused on the treatment of cancer and autoimmune disorders. With successful backing from a group of venture capital firms and US$25 M secured in a recent funding round, Xanthus is in a strong position. Although the firm's business strategy was originally to in-license small novel molecules and advance them to a stage where partnering can be assessed, the acquisition of new molecules has led the firm to adapt this strategy according to the stage of the product in development. For one of Xanthus' molecules, this will involve taking the product through clinical trials.
Drug Delivery: A Solution for Stronger Pipelines (February 2007)In the second PharmaVentures Business Review of 2007, we focus our attention on the drug delivery sector. In the Business Report, we take a look at some of the key trends in drug delivery deal making across the past five years, including the types of deal being signed, the indication areas involved and the changes in overall deal value. We also review the key issues in drug delivery commercialisation and the industry drivers behind growth in this promising sector of the pharmaceutical and biotech industry. In Face-to-Face, Fintan Walton talks to John Patton, CSO and Co-founder of Nektar Therapeutics (then Inhale Therapeutic Systems), about the challenges he faced in setting up the firm, and the company’s success to date.
A review of the key drug delivery deals and transactions in February.
A review of deal making trends in drug delivery over the past five year, the key deals involved, drivers for growth in the drug delivery sector and key issues to consider in drug delivery commercialisation.
Fintan Walton talks to John Patton, CSO and Co-founder of Nektar Therapeutics about the challenges he faced in setting up the firm and the company’s success to date. Roche:Synosis Deal - Birth of an Innovative Business Strategy (February 2007)Fintan Walton talks to Tom Woiwode, VP Business Development & Strategy, Synosis Therapeutics about the unique business model behind the creation and launch of Synosis in January 2007. They discuss how Synosis have secured a five-product portfolio of potential CNS therapeutics from Roche's development pipeline and raised US$32 million in seed and series A financing. Tom outlines how Brad Bolzon, Managing Director of Versant Ventures (the founding investor in Synosis) and previously Executive VP, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche, developed the ideas behind the creation of Synosis. Brad, also Chairman of the Board for Synosis, managed the creation of the firm from inception to launch. In this special interview, the company's business plan is reviewed, as is the firm's overall development going forward. This includes Synosis' intention to take some of their products all the way to launch by developing their own sales and marketing capabilities.
Vice President, Business Development & Strategy Tom has an investment background in biotechnology, having joined Synosis from one of the founding investors, Versant Ventures. Tom spent four years with Versant, helping to inform investment decisions. Prior to Versant, he helped to develop and implement an innovative technology at Xenoport, a leading early-stage biotech company. The technology was focused on improving the gastrointestinal absorption of both small molecule and macromolecular therapeutics. He spearheaded the development of a powerful new high-throughput screening technology, which was subsequently patented and published, and patented new chemistries regarding the absorption of small molecules. Tom additionally focused on crafting Xenoport's early business development strategies, where he evaluated the technical feasibility and commercial impact of internal research programs. Tom graduated from UC Berkeley summa cum laude with highest honors for his BA in English. He earned the Departmental Citation for his BSc in Chemistry and earned his PhD in Chemistry from Stanford University as an NSF fellow. The Year in Review: The Deals and Trends of 2006 (January 2007)In the first PharmaVentures Business Review of 2007, we take a retrospective look across 2006. We review a number of the key deals and transactions from 2006 and what they have meant for the companies involved. In The Business Report we investigate some of the trends in deal making for 2006, putting them into the context of deal making across the last 10 years of industry activity. We also review biotech IPO performance in 2006 and discuss some of the key industry drivers over the year. In Face-to-Face, Fintan Walton talks to Rob Wills, VP Alliance Management, Pharmaceuticals Group, Johnson & Johnson about meeting the challenges of alliance management and ensuring success in partnerships.
A review of some of the major deals and transactions of 2006 An review of deal-making trends in 2006, an overview of biotech IPO performace and a discussion of the key industry drivers. Fintan Walton Talks to Rob Wills, VP Alliance Management, Pharmaceuticals Group, Johnson & Johnson, about meeting the challenges of alliance management and ensuring success in partnerships. PharmaTelevision: The Story So Far (January 2007)
In an interview with Ann Salter, Fintan Walton, CEO, PharmaVentures, looks back at the successful creation of PharmaVentures Business Review and discusses its growth and development since its launch in May 2006. He highlights the aims and strategy surrounding the formation of PharmaTelevision and outlines his plans to expand and develop the concept in 2007, with the addition of new channels and even more content. Meet the Experts Special: Biotech in Australia and New Zealand (January 2007)
In this ‘Meet the Experts’ special, Fintan Walton is joined on the panel by Colin Dawson, CEO of Otago Innovation and David Williams, CEO of Chemeq. Together, they discuss a variety of important issues that face the biotechnology industry in Australia and New Zealand. They talk about the current climate for early-stage financing of start-up companies and the problems that many companies have when they enter the public markets via the ASX. They also talk about the bidirectional opportunities for partnering Australian or New Zealand companies with their European, US and South-East Asian counterparts. The Challenge of Technology Transfer and University Spin-Outs (December 2006)The focus of the December edition of PharmaVentures Business Reviews is Technology Transfer and University Spin-Outs. Our guests this month are:
A round-up of the most interesting and important biotech and pharmaceutical deals that have been signed over the past month. This month, Fintan Walton reviews the technology transfer process and examines the deal-making trends in the technology transfer sector. Fintan Walton leads our panel of experts in a discussion about the current status of the technology transfer sector and the challenges of commercialising valuable IP via the formation of start-up companies. Dr Alice Huxley, CEO & President, Speedel (December 2006)Dr Alice Huxley talks to Fintan Walton about setting up Speedel and her motivations for doing so, following the merger of Ciba-Geigy and Sandoz in 1996 to create Novartis. They discuss the company's drug development programmes and how its lead compound is nearing launch. Dr Huxley also reviews the company’s business strategy and the important balance between collaborative R&D and in-house development. Finally, she outlines the reasoning behind the decision to float Speedel on the Swiss stock exchange and discusses what the future might hold for the small biotechnology company.
Matthew Gardner, President, BayBio (December 2006)To coincide with the launch of the 2007 BayBio:IMPACT report, Matthew Gardner, President of BayBio, Northern California's Life Science Trade Association, talks to Fintan Walton about the role that BayBio plays in serving the life sciences industry in the Bay area of Northern California – the birthplace of the biotech industry. BayBio has 300 member companies, and Matthew outlines the features of this community that have contributed to its successful development. With approximately 370 products in Phase II and III development, and many new products coming to market, the biotech companies in the region are entering an exciting and challenging era in which, after 30 years of research, they are hoping to capitalise on their past success.
Rob Hockney, Director of Alliance Management, Global Discovery Alliances, AstraZeneca (November 2006)Rob Hockney talks to Fintan Walton about the ongoing evolution of AstraZeneca's alliance management strategy and capabilities, and the increasingly important role that dedicated alliance management plays in the drug development process for big pharma and small biotech companies alike. Rob emphasises the need for flexibility when developing an alliance management strategy and the importance of dialogue between partnering companies. Together, they examine the different metrics by which to measure alliance success and consider how termination does not have to be the end of a potentially profitable relationship. They also discuss the characteristics of an alliance that enables first-class management to make a value-generating difference. In addition, Rob highlights the essential role that alliance management plays in bridging the gap between companies with big differences in size and culture.
Stephen Farr, President & COO, and Jonathan Rigby, VP Business Development, Zogenix. (November 2006)Stephen Farr and Jonathan Rigby, two members of Zogenix's founding team, talk to Fintan Walton about setting up the company and the novel, needle-free injection technology platform on which it is based. They discuss Zogenix's business model for becoming a speciality pharmaceutical company and outline their plan to drive their lead product to an NDA filing. Stephen and Jonathan provide an overview of the Intraject® technology and of the company's plan to form strategic partnerships in order to produce novel products and add value to existing therapies. Zogenix's plan to develop its own specialist sales force for the US market as well as its intention to seek a co-promotion partner for entrance into Europe are also covered.
Alliance Management: An Exclusive Interview with Roche (November 2006)In the November 2006 edition of the PharmaVentures Business Review we take a look at Alliance Management. We review the key components that are needed for successful partnering as well the various strategic approaches that can be used to aid in alliance management. In our exclusive Face-to-Face interview, Fintan Walton talks to Eric de la Fortelle, Global Head, External Research and Technology, F. Hoffmann-La Roche, about his role within the Pharma Partnering Group. Eric outlines the structure of the Pharma Partnering Group and Roche's overall model for alliance management. The discussion covers Roche's long-term alliance with Morphosys and the integrated approach that has allowed the companies to harness both science and business, and develop and maintain a successful alliance. Eric also highlights the importance of flexibility in management strategy when assesing alliance candidates and gives an overview of what Roche looks for in a potential partner. In addition to this episode, we continue the theme of Alliance Management in our exclusive interview with Dr Simon Moroney, CEO, MorphoSys Simon Moroney talks to Fintan Walton about the founding and history of MorphoSys, its alliance management model and the challenges of maintaining successful partnerships in parallel with internal drug development programmes. They discuss MorphoSys' long-term strategic partnership with Roche and the rewards that the relationship has brought both companies, as well as the company's strategy going forward. Dr Moroney also outlines MorphoSys’ drug development programme and the strategic reasoning behind the company’s decision to drive growth by business acquisitions in the US. Finally, the impact that the recent consolidation of mid-sized German pharmaceutical companies might have on MorphoSys ongoing scheme of operations is discussed.
A round-up of the most interesting and important biotech and pharmaceutical deals that have been signed over the past month. This month's Business Report discusses the essential components required for successfull alliance management. Fintan Walton talks to Eric de la Fortelle, Global Head, External Research and Technology, F. Hoffmann-La Roche, about the Pharma Partnering Group at Roche and its long standing alliance with Morphosys. Dr Simon Moroney, CEO, MorphoSys (November 2006)Simon Moroney talks to Fintan Walton about the founding and history of MorphoSys, its alliance management model and the challenges of maintaining successful partnerships in parallel with internal drug development programmes. They discuss MorphoSys' long-term strategic partnership with Roche and the rewards that the relationship has brought both companies, as well as the company's strategy going forward. Dr Moroney also outlines MorphoSys’ drug development programme and the strategic reasoning behind the company’s decision to drive growth by business acquisitions in the US. Finally, the impact that the recent consolidation of mid-sized German pharmaceutical companies might have on MorphoSys ongoing scheme of operations is discussed.
Peter Cook, CEO and Managing Director, Biota (November 2006)Peter Cook talks to Fintan Walton about Biota's ongoing business strategy and drug development programmes. Mr Cook discusses the various challenges that biotech companies must face in order to remain successful, including the necessity to balance diversification and specialisation, and the risks and rewards of raising capital in overseas markets. They also talk about Biota's success with Relenza™ and the ongoing management of its relationship with GlaxoSmithKline, as well the licensing of Biota's lead RSV compound to MedImmune.
Richard de Souza, Chief Executive Officer, Archimedes Pharma (October 2006)Richard de Souza talks to Fintan Walton about Archimedes Pharma's unique business and funding model. Mr de Souza gives an insight into how the company's experienced management team was put in place and its proposed time-scales for becoming cash positive. Other aspects of Archimedes' business strategy are also discussed, including the company's aim to effect business acquisitions in the five major European markets.
Dr Mark Ashton, Executive Vice President Business Development, Evotec (October 2006)Dr Mark Ashton talks to Fintan Walton about Evotec's evolving business model, which is based on both contract research services and proprietary research in the CNS field. In particular, they discuss Evotec's successful alliance history with Roche that dates back to 2001. Dr Ashton talks in depth about the terms of these risk-sharing agreements and how they are managed. He also offers an insight into Evotec's future strategic plans.
彭博士， 国际贸易部主任-先声药业，董事-东伟顾问有限公司 （香港） (October 2006)Dr Pang talks to Jing Wang about biotechnology trends in China. He examines what the Chinese pharmaceutical and biotechnology industry has to offer the global market, discusses the opportunities in China and presents his thoughts on the challenges that this region faces. The discussion provides an in-depth analysis and informative overview of this emergent territory, which has lately been the subject of much attention.
Dr H Ming Pang (Head of International Business - Simcere Pharmaceuticals, Inc., Director - Eastway Consultants Ltd HK) (October 2006)Dr Pang talks to Fintan Walton about biotechnology trends in China. He examines what the Chinese pharmaceutical and biotechnology industry has to offer the global market, discusses the opportunities in China and presents his thoughts on the challenges that this region faces. The discussion provides an in-depth analysis and informative overview of this emergent territory, which has lately been the subject of much attention.
Early-Stage Financing (October 2006)In the October 2006 edition of PharmaVentures Business Review, we explore the
current climate of early-stage financing for biotech companies in both the US and European
funding sectors. Our guests this month are:
A round-up of the most interesting and important biotech and pharmaceutical deals that have been signed over the past month. This month, Fintan Walton leads us through an analysis of the trends in early-stage biotech financing in the US. Fintan Walton leads our panel of industry exerts in an in-depth discussion about the early stage financing of biotech companies in Europe. Onno van de Stolpe, CEO, Galapagos (October 2006)Onno van de Stolpe talks to Fintan Walton about Galapagos' current business model and overall strategic outlook. They discuss the integration of BioFocus following its acquisition by Galapagos in November 2005, as well as the more recent acquisition of the drug discovery service division of Discovery Partners International. Onno talks in detail about managing Galapagos' strategic osteoarthritis alliance with GlaxoSmithKline and the challenges the company now faces as it expands its operations across the globe.
Deal Making in Oncology (September 2006)The focus of the September edition of PharmaVentures Business Reviews is deal making in oncology. Our guests this month are:
A round-up of the most interesting and important biotech and pharmaceutical deals that have been signed over the past month. This month's business report looks at trends in deal making within the oncology sector. Fintan Walton leads this month's expert panel discussion on the topic of oncology deal making. An Interview with Fintan Walton (September 2006)In this interview, Ann Salter talks to Fintan Walton, CEO, PharmaVentures, about PharmaVentures' latest strategic intelligence resource for the biotech and pharmaceutical business community: PharmaVentures Business Review. Deal Valuation (August 2006)This month, PharmaVentures Business Review focuses on deal valuation. Our guests this month are:
A round-up of the most interesting and important biotech and pharmaceutical deals that have been signed over the past month. In this month's Business Report, we assess the valuation methodologies used in deal transactions for assets such as drugs in development, whole pipelines or business assets. This month, Fintan Walton leads our expert panel in a discussion about deal valuation. Late-Stage Deals: Phase III and Beyond (July 2006)In July's edition of the PharmaVentures Business Review we turn our attention to late-stage deal making. Our guest this month is Bruce Carter, CEO, ZymoGenetics
A round-up of the most interesting and important biotech and pharmaceutical deals that have been signed over the past month. In the Business Report this month, we investigate the trends in deal making for products that have reached Phase III or later in the development process. Fintan Walton, CEO of PharmaVentures, talks exclusively to Bruce Carter, President and CEO of ZymoGenetics. Going Public: Trends in the IPO Market (June 2006)In this month's edition of the PharmaVentures® Business Review, we take a look at what is happening in the world of biotech initial public offerings. Guests on this month's show:
A round-up of the most interesting and important biotech and pharmaceutical deals that have been signed over the past month. In this month's Business Report, we focus on some of the trends that business analysts at PharmaVentures have been observing in the biotech IPO landscape. Fintan Walton, CEO PharmaVentures, leads this month's international panel in a discussion about IPOs in the biotech industry. Trends in Mergers & Acquisitions (May 2006)PharmaVentures Business Review is a new cutting-edge television business show that provides viewers with effortless access to essential industry intelligence. Guests on this months show include:
A round-up of the most interesting and important biotech and pharmaceutical deals that have been signed over the past month. A focus on some of the trends that PharmaVentures' business analysts have observed in the area of Mergers & Acquisitions between 2000 and 2005. This month's subject is the funding of the Australian biotech industry. Dr Fintan Walton, CEO of PharmaVentures, leads a discussion with our expert panel on the topic of Mergers & Acquisitions within the biotech and pharmaceutical sector. |
|
|
|||
|
If you would like further information about the PharmaVentures Business Review please contact us. PharmaVentures would also like to hear your views on the Business Review. Please send us your comments and feedback. For future editions, we are on the look out for potential panellists from the pharmaceutical, biotech and financial sectors to participate in the PharmaVentures Business Review. If you would like to take part in upcoming shows, please contact us About PharmaVentures Building on over 14 years of international experience and comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence, we work with our clients to drive greater value from their deals. The company is based in Oxford, UK with offices in the USA. |
|||||
|
|||||